ADC Therapeutics (ADCT) Revenue (2021 - 2026)
ADC Therapeutics' (ADCT) quarterly Revenue came in at $19.2 million in Q2 2026, up 2.17% year-over-year from $18.8 million in Q2 2025, and down 7.69% quarter-over-quarter from $20.9 million in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) Revenue (2021 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Revenue across 6 years of filings, most recently posting $19.2 million for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.34 Bn | 192.35 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.22 Bn | 123.37 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.84 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.18 Bn | 49.05 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.22 Bn | 29.91 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.06 Bn | 29.06 Bn | 1.16 Mn | 1.44 Mn |
| 10 | ADC Therapeutics | 171.29 Mn | -47.81 Mn | 17.14 Mn | 19.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.25 Mn |
| Mar 31, 2026 | 20.85 Mn |
| Sep 30, 2025 | 16.43 Mn |
| Jun 30, 2025 | 18.84 Mn |
| Mar 31, 2025 | 23.03 Mn |
| Sep 30, 2024 | 18.46 Mn |
| Jun 30, 2024 | 17.41 Mn |
| Mar 31, 2024 | 18.05 Mn |
| Sep 30, 2023 | 14.49 Mn |
| Jun 30, 2023 | 19.28 Mn |
| Mar 31, 2023 | 18.99 Mn |
| Sep 30, 2022 | 76.32 Mn |
| Jun 30, 2022 | 17.29 Mn |
| Mar 31, 2022 | 46.50 Mn |
| Sep 30, 2021 | 13.15 Mn |
| Jun 30, 2021 | 3.76 Mn |